- Home
- CBNK vs ABVX Comparison
CBNK vs ABVX Comparison
Compare CBNK & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNK
- ABVX
- Stock Information
- Founded
- CBNK 1974
- ABVX 2013
- Country
- CBNK United States
- ABVX France
- Employees
- CBNK 407
- ABVX N/A
- Industry
- CBNK Major Banks
- ABVX
- Sector
- CBNK Finance
- ABVX
- Exchange
- CBNK Nasdaq
- ABVX Nasdaq
- Market Cap
- CBNK 471.8M
- ABVX 407.6M
- IPO Year
- CBNK 2018
- ABVX N/A
- Fundamental
- Price
- CBNK $28.38
- ABVX $6.25
- Analyst Decision
- CBNK Hold
- ABVX Buy
- Analyst Count
- CBNK 1
- ABVX 8
- Target Price
- CBNK $35.00
- ABVX $34.63
- AVG Volume (30 Days)
- CBNK 44.7K
- ABVX 317.1K
- Earning Date
- CBNK 04-21-2025
- ABVX 03-24-2025
- Dividend Yield
- CBNK 1.41%
- ABVX N/A
- EPS Growth
- CBNK N/A
- ABVX N/A
- EPS
- CBNK 2.12
- ABVX N/A
- Revenue
- CBNK $170,671,000.00
- ABVX $11,172,999.00
- Revenue This Year
- CBNK $46.06
- ABVX $306.91
- Revenue Next Year
- CBNK $8.25
- ABVX N/A
- P/E Ratio
- CBNK $13.25
- ABVX N/A
- Revenue Growth
- CBNK 8.71
- ABVX 135.94
- 52 Week Low
- CBNK $19.02
- ABVX $5.50
- 52 Week High
- CBNK $32.88
- ABVX $16.63
- Technical
- Relative Strength Index (RSI)
- CBNK 40.98
- ABVX 40.22
- Support Level
- CBNK $27.02
- ABVX $5.60
- Resistance Level
- CBNK $29.11
- ABVX $7.85
- Average True Range (ATR)
- CBNK 0.79
- ABVX 0.60
- MACD
- CBNK 0.04
- ABVX -0.05
- Stochastic Oscillator
- CBNK 44.41
- ABVX 28.89
About CBNK Capital Bancorp Inc.
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.